August 29, 2026 07:51 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Clean my shoes’: Greater Noida woman detained after alleged abuse, assault of security guards | 21-year-old model stabbed to death in Delhi; gym trainer arrested after encounter | Abhishek Banerjee, Derek O'Brien, other TMC leaders booked after Camac Street clash with Kolkata Police | Kanpur plane crash: Training aircraft crashes near Ganges, two pilots killed | Big IT boost for Bengal: LTM opens global delivery & AI centre in Kolkata's New Town | 21-year-old Delhi model found stabbed at Delhi home, gym trainer accused of killing her | ‘Who is stopping her from wearing what she wants?’: Kangana Ranaut hits back at Kriti Sanon over Raksha Bandhan ad | 300 Indians missing in Nepal flash floods, 160 dead: Foreign Minister reveals grim toll | Supreme Court directs Tarun Tejpal to surrender within two weeks | Supreme Court notice to 20 rebel TMC MPs in disqualification plea
COVAXIN

Covaxin's efficacy result will help getting WHO's approval : Govt expert body chief

| @indiablooms | Jul 04, 2021, at 02:04 am

New Delhi/IBNS: India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said on Saturday.

“This will help to get the vaccine WHO emergency use listing,” Arora told news agency ANI.

The NTAGI chairman also said the approval from the UN health body will bring visibility to India since Covaxin is indigenously developed.

Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech made the claim in the phase three clinical trial data of the vaccine.

The company has further claimed Covaxin is 93.4% effective against severe symptomatic COVID-19 cases, 63.6% against asymptomatic COVID-19 cases and 65.2% against the Delta variant.

“Efficacy analysis demonstrates Covaxin to be 77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic Covid-19,” the manufacturer said in a paper published in open access journal medRxiv.

"We are working closely with the World Health Organisation for inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," Ella tweeted.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.